One way or the other - we will find out.
According to Google's AI - When I asked the question "Approximately how many patients are enrolled in a phase II clinical trial for a new medical drug?"
It came back with the answer as follows:
"Phase II clinical trials for a new medical drug typically enroll between 100 and 300 volunteers who have the disease or condition the drug is intended to treat. These studies are designed to evaluate effectiveness and assess safety, usually involving a few hundred patients, though in some cases, such as specific cancer studies, this number may be fewer than 100." Citation traces back to the FDA website.
So I would guess that Diwan falls back on a smaller size group. The 'good news' here is that the treatment should either work, or not work, quickly.
Market Data 
Markets 
AI
